lisocabtagene maraleucel
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
FDA Approves Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
The FDA has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, a Bristol Myers Squibb company) for ...
MAY 31, 2024
FDA Grants Accelerated Approval to Breyanzi for Follicular Lymphoma
The FDA has granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics) for adults with ...
MAY 17, 2024
Breyanzi Approved for Adults With Relapsed/Refractory CLL or SLL
The FDA granted accelerated approval of lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), a CD19-directed ...
MARCH 19, 2024
New CAR T-Cell Therapy Approved for LBCL
The FDA approved lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), a CD19-directed chimeric antigen ...
JUNE 24, 2022
CAR T-Cell Therapy Proposed as New Standard for Second-Line in Relapsed B-cell Lymphoma
Lisocabtagene maraleucel (liso-cel) (Breyanzi, Bristol Myers Squibb) will emerge as the standard of care (SOC) for ...
JUNE 6, 2022
New CAR T-Cell Therapy Breyanzi Approved for R/R B-Cell Lymphoma
The FDA approved the CD19-directed chimeric antigen receptor T-cell immunotherapy lisocabtagene maraleucel ...
FEBRUARY 12, 2021
